Risk of atrial fibrillation and stroke among older men exposed to prolonged endurance sport practice: a 10-year follow-up. The Birkebeiner Ageing Study and the Tromsø Study

Kristoffer Robin Johansen ,1,2 Anette Hylen Ranhoff,3,4 Eivind Sørensen,4,5 Bjarne M Nes,6 Kim Arne Heitmann 1,7 Turid Apelland,5 Silvana Bucher Sandbak,7 Tom Wilsgaard,8 Maja-Lisa Løchen 1,8,9 Dag S Thelle,10,11 Bente Morseth 1,2 Marius Myrstad,5,12 On behalf of the NEXAF initiative

ABSTRACT

Aims Endurance sport practice is associated with a high prevalence of atrial fibrillation (AF), which increases the risk of stroke in the general population. However, stroke risk in endurance athletes with AF is sparsely investigated. Most studies have been limited by design and are largely restricted to younger and middle-aged populations. Thus, we aimed to investigate AF and stroke risk in older athletes exposed to prolonged endurance training.

Method During a 10-year period, 505 male athletes aged ≥65 years frequently participating in a long-distance ski race were compared with 1867 men of the same age from the general population. The main exposure was endurance sport practice with self-reported AF and stroke as outcomes. Stroke risk was further examined by joint modelling of AF and endurance practice. Statistical analysis was conducted with a modified Poisson model.

Results Athletes (median age: 68, range: 65–90) participated in a long-distance ski race over a median of 14 years (range: 1–53). Prevalence (28.5% vs 17.8%) and adjusted risk of AF (risk ratio (RR): 1.88, 95% CI: 1.49 to 2.37) were higher in athletes compared with non-athletes, whereas the prevalence (5.4% vs 9.7%) and risk of stroke were lower (RR: 0.60, 95% CI: 0.37 to 0.95). Compared with athletes without AF, risk of stroke was twofold in athletes (RR: 2.38, 95% CI: 1.08 to 5.24) and nearly fourfold in non-athletes (RR: 3.87, 95% CI: 1.98 to 7.57) with AF.

Conclusion Although older male endurance athletes experienced an increased risk of AF, the long-term risk of stroke was substantially reduced compared with non-athletes.

INTRODUCTION

Atrial fibrillation (AF) is the most common cardiac arrhythmia worldwide.1 AF is associated with a substantially elevated risk of cardioembolic stroke,2 particularly in the presence of concomitant cardiovascular risk factors. In contrast, there is an inverse dose-response association between physical activity (PA) and cardiovascular disease.3,4 and moderate levels of PA are also associated with a decreased risk of AF.5,6 However, high levels of vigorous PA and particularly systematic endurance exercise are associated with an increased risk of AF, even in the absence of established risk factors.7,8 resulting in a high AF prevalence in male endurance athletes.10 Although not fully understood, the risk of exercise-related AF is probably linked to cardiac remodelling.
caused by repetitive exposure to high blood volumes and pressures during endurance exercise.\textsuperscript{7}

The majority of previous studies have been limited by retrospective or cross-sectional designs and are largely restricted to young and middle-aged male athletes, with a limited period of exposure to endurance sport practice. The long-term risk of AF and stroke in older recreational athletes exposed to prolonged endurance sport practice has been sparsely investigated. Myrstad \textit{et al.}\textsuperscript{10} observed an increased risk of AF in endurance athletes aged ≥65 years in a cross-sectional investigation. However, whether the risk of AF observed in older endurance athletes translates into an increased risk of stroke remains unclear. In another study that included >200 000 skiers with a mean age of 37 years, AF was associated with an increased risk of stroke during up to 9-year follow-up, but the absolute risk of stroke was very low.\textsuperscript{8}

In the present study, we aimed to examine the cumulative prevalence and risk of self-reported AF and stroke related to leisure-time PA and endurance sport practice during an 8-year to 10-year follow-up among older male recreational cross-country skiers compared with men of similar age representing the general Norwegian population.

\textbf{METHOD}

\textbf{Design and study population}

The current study comprises two prospective cohorts, one consisting of men aged ≥65 years who participated in the Birkebeiner Ageing Study (BiAS),\textsuperscript{10} the other is a sample of men in the same age group included from the sixth wave of the population-based Tromsø Study (Tromsø6, 2007–2008).\textsuperscript{12} In total, our pooled study sample included 2372 participants.

BiAS is a prospective cohort study that included participants competing in the Birkebeiner cross-country ski race, an arduous competition extending over 54 km with >1000 uphill altitude metres.\textsuperscript{10} In total, 658 (n=607 male, n=51 female) athletes who completed the race in 2009–10 and were aged ≥65 years at that time were invited to participate. In the current analyses, we included men only as there were few eligible female athlete participants. In total, 509 athletes agreed to participate, and 505 (83%) were included (figure 1).

The athletes received a questionnaire that was filled out and returned by post. A follow-up questionnaire was distributed in 2014 and 2020, allowing examination of AF and stroke during a 10-year follow-up. Seventy-nine (15.6%) participants did not respond to the follow-up in 2014. Furthermore, 152 (30.1%) participants did not respond to the follow-up in 2020 (online supplemental table 1), out of which 115 did not reply, while 37 were dead. In total, 87.7\% (n=443) of participants responded to follow-up either in 2014 (17.8\%), 2020 (3.4\%) or both (66.5\%).

The Tromsø Study is a population-based study with repeated surveys with participants from the municipality of Tromsø, Norway.\textsuperscript{12} Participants in the Tromsø Study are considered representative of a northern European white urban population.\textsuperscript{13} Of all male inhabitants aged 65–87 years who were invited to participate in Tromsø6 (n=2757), 1867 (68\%) attended and were included in the current study. Data on AF and stroke were available from the seventh Tromsø survey (Tromsø7, 2015–16), which allowed assessment of outcomes after 8 years. Out of attending participants in Tromsø6, 834 participants (44.7\%) did not attend the follow-up examination in Tromsø7 (online supplemental table 1), 429 of these were invited but did not attend, 354 were dead and 51 had moved out of the municipality.

\begin{figure}[ht]
\centering
\includegraphics[width=\linewidth]{flowchart}
\caption{Flow chart of participants included in the study. The Birkebeiner Ageing Study and the Tromsø Study. AF, atrial fibrillation.}
\end{figure}
Exposures and outcomes
The main exposure was participation in the Birkebeiner race, dichotomised into athletes versus non-athletes. Secondary exposure variables were years of race participation (annual Birkebeiner races completed), medals achieved in the Birkebeiner race and self-reported leisure-time PA. A medal is achieved when a participant completes the race within the average race time +25% of the top five performers in their respective 5-year age class. In both BiAS and Tromsø6 and Tromsø7, self-reported leisure-time PA was assessed by the Saltin-Grimby Physical Activity Level Scale (SGPALS), which assesses PA on a 4-level scale (1=sedentary, 2=light, 3=moderate, 4=vigorous). The questionnaire has been thoroughly validated and has to a moderate extent discriminative ability in terms of an individual’s VO₂max.

The main outcomes were self-reported AF and stroke reported at least once either at baseline (Tromsø6 and BiAS 2009/2010) or during follow-up (Tromsø7, and BiAS 2014 and/or BiAS 2020). BiAS participants were asked “Do you have, or have you ever had atrial fibrillation?” and were given the following alternatives ‘yes, once’, ‘yes, several times’, ‘yes, I have it chronically’ or ‘no’. All three ‘yes’ alternatives were subsequently merged into a single category before analysis. Tromsø6 participants were asked the same question with response options ‘yes’ or ‘no’. Furthermore, confirmed AF diagnoses by electrocardiography were retrieved from medical hospital records at the University Hospital of North Norway (for Tromsø Study participants only) and used in supplementary analyses. Self-reported stroke was based on the question “Do you have or have you ever had a stroke?”, with either ‘yes’ or ‘no’ as possible answers. The question differed slightly at follow-up for BiAS participants as they were asked to answer if they had experienced a stroke only. Thus, in line with the skip pattern participants in BiAS with missing data for stroke at follow-up were treated as ‘no’.

Participants with missing data on AF and/or stroke at either baseline or follow-up were included in the analysis, whereas participants with missing data at all examination points were excluded from the analysis.

Covariates
In Tromsø6, height and weight were measured to the nearest centimetre and half kilo with participants wearing light clothing without shoes. In BiAS, height and weight were self-reported. Body mass index was calculated as weight divided by the square height in centimetres. All other covariates were obtained by self-report in both cohorts. Education, smoking and alcohol frequency questions differed slightly between the cohorts as there were more alternatives in the BiAS questionnaire. As such, they were collapsed into harmonised categories. Additionally, participants were asked “Do you take blood pressure lowering medication?” Coronary heart disease (CHD) was assessed by two questions: “Do you have, or have you had angina pectoris?” and “Do you have, or have you had a heart attack?” Diabetes was examined by the question “Do you have, or have you had diabetes?” The questionnaires are described in detail elsewhere.

Statistics
Participants from BiAS and the Tromsø Study were analysed together in a pooled cohort. Descriptive characteristics for continuous variables are given as median (25th and 75th percentile) and categorical variables as percentages. Differences between groups for baseline covariates were assessed by independent-samples Mann-Whitney U test for continuous variables and by Pearson’s χ² test for categorical variables. The cumulative prevalence of AF and stroke were defined as all participants still alive at follow-up who reported an outcome at least once during the study period divided by all participants who attended the baseline survey and were still alive at follow-up. We examined associations between exposures and outcomes with a Poisson loglinear regression analysis with robust SEs where parameter estimates are given as risk ratios (RR) and corresponding 95% CIs. To identify adjustment variables, directed acyclic graphs were drawn using the web application DAGitty (www.dagitty.net) (online supplemental figures 1–4). In addition to an age-adjusted model, we present a total effect model (model 2) and a direct effect model (model 3). Model 2 is adjusted for age, body height, education, smoking status and frequency of alcohol consumption. Model 3 is adjusted for model 2+CHD, diabetes, body mass index and antihypertensive medication, aiming to examine exercise-related outcomes. RR were estimated during a 10-year follow-up for AF and stroke. We present estimates for athletes compared with non-athletes as the reference and estimates for races completed and medals achieved per 10-unit increase among athletes with the lowest number of races or medals as the reference. Furthermore, AF risk for joint categories of endurance sport practice and SGPALS are presented (1=non-athletes inactive, 2=non-athletes light, 3=non-athletes moderate to vigorous, 4=athletes light, 5=athletes moderate to vigorous). In addition, we categorised participants by AF status in both cohorts and examined stroke risk in four groups (1=athletes without AF, 2=non-athletes without AF, 3=athletes with AF, 4=non-athletes with AF). The significance level was set at 0.05. All statistical analyses were performed with Stata V.17 (StataCorp, Texas, USA).

Sensitivity analyses
We performed sensitivity analyses by excluding participants who reported CHD and diabetes at baseline. Furthermore, to account for a larger loss to follow-up in the Tromsø Study compared with BiAS, sensitivity analyses were performed by including non-attendees of Tromsø7 (follow-up) who developed AF during the study period according to ECG confirmed AF diagnoses from the University Hospital of North Norway (online supplemental table 3). To further assess the robustness of the estimated AF risk, we removed all participants with ≥1 AF risk factor (smoking, overweight, hypertension, diabetes...
and CHD) and reran model 3 (online supplemental table 4). We also reanalyzed the risk of AF and stroke after exclusion of participants aged >75 years to account for possible issues related to recall bias (online supplemental table 5).

RESULTS

Descriptive characteristics for participants at baseline are given in Table 1. On average, athletes were 2.6 years younger, 4.2 cm taller, 6.7 kg lighter and more educated than non-athletes. Athletes were less often current or previous smokers and had a very low prevalence of cardiovascular risk factors and conditions, such as CHD, diabetes and use of antihypertensive medication. Athletes reported that they had participated in the Birkebeiner race over a median of 14 years (range: 1–53) and had been practising regular systematic endurance training over a median of 36 years (range: 0–67), with nearly one-fourth (24%) reporting systematic endurance training for at least 50 years. Ninety per cent (n=443) of athletes reported either moderate or vigorous PA during past 12 months. Two athletes had missing data for races, 5 were missing data for medals and 13 did not report PA. There were 245 (13.1%) non-athletes with missing data on PA.

<table>
<thead>
<tr>
<th>Baseline characteristics</th>
<th>Tromsø6 (n=1867)</th>
<th>BiAS (n=505)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>70 (67–75)</td>
<td>68 (66–71)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>174.5 (170.1–178.8)</td>
<td>178.0 (175.0–182.0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>81.2 (73.4–89.9)</td>
<td>75.0 (70.0–80.0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>26.8 (24.4–29.1)</td>
<td>23.5 (22.2–24.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Number of Birkebeiner races completed</td>
<td>–</td>
<td>14 (7–27)</td>
<td></td>
</tr>
<tr>
<td>Number of achieved Birkebeiner medals</td>
<td>–</td>
<td>6 (0–21)</td>
<td></td>
</tr>
<tr>
<td>Total years of systematic endurance training</td>
<td>–</td>
<td>36 (19.0–49.0)</td>
<td></td>
</tr>
</tbody>
</table>

Values are presented as median (25th and 75th percentile) for continuous variables and as percentages for categorical variables. AF risk factor variable: one or more of the following: BMI ≥25 kg/m², current smoker, current use of antihypertensive medication, diabetes and coronary heart disease.

AF, atrial fibrillation; BMI, body mass index.
During the study period, 470 (20.3%) individuals reported AF. The cumulative AF prevalence was 17.8% for non-athletes and 28.5% for athletes. In the age-adjusted analysis, the RR of AF was 1.64 (95% CI: 1.38 to 1.95) for athletes compared with non-athletes. After multivariable adjustment (model 2 and 3), the RR for AF was 1.42 (95% CI: 1.17 to 1.73) and 1.88 (95% CI: 1.49 to 2.37), respectively (table 2). We did not observe any statistically significant association between AF and number of races completed or medals achieved. When modelling AF risk by joint associations of leisure-time PA during the past 12 months and years of endurance sport practice, we observed a non-linear dose-response association (figure 2, p<0.05), with the highest risk of AF observed among athletes reporting vigorous PA. In sensitivity analyses, we added incident AF cases according to hospital records and found that the cumulative AF prevalence increased to 22.5% for non-athletes, and the relative risk of AF in athletes versus non-athletes decreased (model 3—RR: 1.52, 95% CI: 1.24 to 1.88). Excluding participants with at least one risk factor for AF did not result in a meaningful change of the estimated risk of AF.

In total, 211 (9.1%) participants reported a stroke, with a cumulative prevalence of 9.7% in non-athletes and 5.4% in athletes. Although the age-adjusted RR was 0.60 (95% CI: 0.41 to 0.89), the association between endurance sport practice and stroke was not significant (model 2—RR: 0.69, 95% CI: 0.45 to 1.04) after multivariable adjustment (online supplemental table 6). However, after excluding participants with CHD and diabetes at baseline the association reached statistical significance (RR: 0.60, 95% CI: 0.37 to 0.95). The estimated risk reduction was diminished after further adjustment in model 3 (RR: 0.76, 95% CI: 0.47 to 1.24). The cumulative prevalence of stroke was 8.3% in athletes with AF and 14.2% among non-athletes with AF. Compared with athletes without AF the estimated risk of stroke was increased in non-athletes without AF (RR: 2.38, 95% CI: 1.04 to 5.24) and non-athletes with AF (RR: 3.87, 95% CI: 1.98 to 7.57), respectively (figure 3).

Restricting the analysis to participants ≤75 years did not change the estimated risk of AF and stroke.

**DISCUSSION**

This study is to our knowledge the first to assess long-term AF and stroke risk prospectively in older men with a history of long-term endurance sport practice. Although prolonged endurance sport practice was associated with an increased risk of AF in older men during long-term follow-up, the risk of stroke was decreased. Relative to athletes who did not report AF during the study period, the risk of stroke was higher in both athletes and non-athletes reporting AF, as well as for non-athletes who did not. Furthermore, although not statistically significant, the estimated risk appeared higher in non-athletes with AF compared with athletes with AF, which may suggest that athletes with exercise-related AF are less susceptible to stroke than their non-athletic counterparts with AF.
Long-term endurance sport practice and risk of atrial fibrillation

Our results corroborate other findings reporting a high prevalence of AF among endurance athletes. AF prevalence in older male endurance athletes has previously been reported to be similar to that of the general population despite a lower overall risk of cardiovascular disease. Furthermore, Grimsmo et al reported an AF prevalence of 17% in another cohort of Birkebeiner skiers aged 26–64 years during 28–30 years follow-up. However, that study had a small sample and no reference population. In comparison to the general population, our study indicates that the cumulative prevalence of AF increases at a faster rate in the older athletic population.

The accumulating prevalence of AF in older male athletes is likely due to an elevated risk of AF associated with endurance sport practice as pointed out by the majority of the research literature. However, most studies are limited by small sample sizes with few AF cases resulting in a large degree of uncertainty for the estimated risk. In a recent prospective study on middle-aged skiers, the AF risk increase associated with endurance sport practice was 11% for men. Considering that we observed a twofold AF risk increase associated with endurance sport practice, our findings might suggest that the risk difference between athletes and the general population is magnified with age. The exercise-related cardiac remodelling claimed responsible for AF in athletes may require several years to manifest and be more pronounced in older athletes with prolonged exposure to exercise, and thus may explain a higher risk for athletes in the present study. This notion is further supported by a retrospective cohort study including Birkebeiner skiers, where the odds of AF increased by 16% per 10 years of regular endurance exercise, an increase that did not appear to plateau until the fourth decade of endurance training.

Joint associations between endurance sport, physical activity and atrial fibrillation

Similar to several previous investigations, we observed a J-shaped association between levels of PA and AF. The benefit of moderate amounts of PA was less clear in our study compared with others. Mozaffarian et al reported a >50% lower AF risk with increasing levels of PA among 5446 individuals aged ≥65 years. In contrast, a study from the third Tromsø survey observed no association between PA and AF in individuals aged >50 years. The same age interaction was observed in the Physicians Health Study, where no association between exercise and the risk of AF was found for men aged >50 years. Notably, Drca et al reported results similar to our study, indicating a 13% reduced risk of AF associated with walking/bicycling ≥1 hour per day in a cohort of 44,410 men. Thus, based on our findings and others, the effect of moderate PA doses on AF risk appears beneficial in older adults.

Risk of stroke

We observed a considerably lower stroke prevalence among athletes than non-athletes. This difference corresponds with but also supersedes previous results based on middle-aged endurance athletes. The athletes in the present study had a substantially lower prevalence of established risk factors for stroke such as hypertension, overweight, diabetes and CHD than the non-athletes, which suggests that the effect of endurance sport practice was largely but perhaps not solely mediated by its effect on these risk factors.

Although our results alluded to a reduced risk of stroke among athletes, we observed a twofold increased stroke risk in athletes with AF compared with athletes without AF, indicating that AF increases the stroke risk also in athletes. Nevertheless, we also observed that the prevalence of stroke was nearly doubled in non-athletes with AF compared with athletes with AF, suggesting that AF is less serious in athletes. Furthermore, relative to athletes without AF, the estimated stroke risk was nearly fourfold in non-athletes with AF, further indicating that exercise mitigates the risk of stroke in patients with AF. Our results corroborate the findings of Svedberg et al and extend this notion to older athletes. Collectively, these results suggest that exercise-related AF involves a lower risk of stroke than AF related to traditional cardiovascular risk factors.

Strengths and limitations

The main strength of the present study is the unique cohort of older Birkebeiner participants that should be considered representative of individuals exposed to long-term systematic endurance training. Nearly one-fourth of...
athletes reported systematic endurance training for more than half a century, with the most experienced athlete reporting nearly seven decades of endurance training. Furthermore, including a reference group representative of the Norwegian population enabled us to indicate risk of AF and stroke relative to the general population. Another strength is that we had multiple covariates available for adjustment. However, most of these were self-reported and residual confounding due to incomplete adjustment in addition to unobserved factors cannot be excluded.

A sizeable number of participants did not attend follow-up, and a larger proportion of athletes than non-athletes responded to the follow-up assessment, likely causing overestimation of AF and stroke risk in athletes. We attempted to remedy this in a sensitivity analysis that included incident AF cases according to hospital-confirmed AF diagnoses which were available in the Tromsø Study. This resulted in a higher AF prevalence among non-athletes comparable to the older Norwegian population. Then again, this analysis may conversely underestimate AF risk in athletes as we could not account for those who did not attend follow-up in BiAS in the same manner. Furthermore, such a sensitivity analysis was not possible for stroke. Another limitation is that AF and stroke were self-reported. The sensitivity for self-reported AF and stroke is approximately 50%–70% and 80% in the general population, respectively. Moreover, as athletes might possibly be more sensitive to symptoms related to arrhythmias, overestimation of AF risk compared with non-athletes may have occurred. However, it has also been suggested that AF in athletes can be less symptomatic. Unfortunately, comparable data about management such as oral anticoagulation therapy to prevent stroke and subtypes of AF were not available. Thus, we cannot exclude that relevant differences between the two groups in terms of treatment of AF could have affected the risk of stroke.

The somewhat shorter follow-up time in the reference population may have overestimated the relative risk of AF and stroke in BiAS participants, although a small portion of participants from BiAS only had follow-up from 2009–10 until 2014. Another limitation is that we used self-reported PA as a secondary exposure. Questionnaire-based PA is prone to recall and social desirability bias, and therefore the effect of PA may have been underestimated. Consequently, the association between PA and risk of AF may have been biased towards the null. To mitigate the problem of missing participants at follow-up in addition to a somewhat limited sample of endurance athletes, we used RRs based on baseline prevalence in addition to incidence of outcomes at follow-up, enabling us to include all participants who gave an answer at one of the measurement points. This may increase the risk of reverse causation bias; however, as the main exposure (endurance sport practice) largely preceded the baseline assessment for the majority of athletes, we assume that the concept of temporality was of limited concern. Finally, we are limited by the inclusion of men only, as several studies have observed an interaction with gender in relation to the endurance sport practice and AF association.

CONCLUSION
This prospective study substantiates previous research showing a high prevalence and an increased risk of AF in older men exposed to prolonged endurance sport practice. Despite a higher risk of AF, we observed that endurance athletes had a lower risk of stroke than non-athletes, and we found further indications that athletes with AF may have a lower risk of stroke than non-athletes with AF. Further prospective studies should address underlying pathophysiological mechanisms for exercise-related AF and risk of stroke related to this entity of AF.

Author affiliations
1School of Sport Sciences, UiT The Arctic University of Norway, Tromso, Norway
2Centre for Research and Education, University Hospital of North Norway, Tromso, Norway
3Department of Clinical Science, University of Bergen, Bergen, Norway
4Department of Internal Medicine, Diakonhjemmet Hospital, Oslo, Norway
5Department of Medical Research, Barum Hospital, Vestre Viken Hospital Trust, N-1346 Gjøttum, Norway
6Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway
7Department for Teacher Education, Norwegian University of Science and Technology, Trondheim, Norway
8Department of Community Medicine, UiT The Arctic University of Norway, Tromso, Norway
9Department of Cardiology, University Hospital of North Norway, Tromso, Norway
10Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
11School of Public Health and Community Medicine, Institute of Medicine, University of Gothenburg Sahlgrenska Academy, Goteborg, Sweden
12Department of Internal Medicine, Barum Hospital, Vestre Viken Hospital Trust, N-1346 Gjøttum, Norway

Twitter Kristoffer Robin Johansen @KristofferRJ89, Kim Arne Heitmann @KimHeitmann, Bente Morseth @MorsethBente and Marius Myrstad @MariusMyrstad

Acknowledgements We thank Ida Kristine Sagnes, Astrid Hylen Klippenberg and Andreas Henriksson for their invaluable contribution with collection and processing of the Birkebeiner Ageing Study data material. We thank the participants in the Birkebeiner Ageing Study and the participants in the Tromsø Study for their contribution.

Collaborators This work has been done within the framework of the Norwegian Exercise and Atrial Fibrillation Initiative (NEXAF) project (https://nexaf.no), which is a collaborative research initiative aiming to increase knowledge about physical activity and exercise in relation to atrial fibrillation. The NEXAF initiative: Bente Morseth1,2, Marius Myrstad4,5, Bjarne Martens Nes5, Jan Pål Lønneche6, Maja-Lisa Løchen7, Arnljot Tveit8, Turid Apelland9, Kristine Folkenborg9, Kristoffer Robin Johansen1,2, Kristin Espolin Johnson5, Jon Magne Lønnes6, Vegard Malmo6, Andreas Berg Sellevold6, Elvind Sørensen9, Rune Brykjeld10,4, Steve Enger10, Hilde Larhammer3,4, Sophia Onarheim4, Vigdis Bache-Semb5. Affiliations: 1School of Sport Sciences, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromso, Norway. 2Centre for Research and Education, University Hospital of North Norway, Tromso, Norway. 3Department of Internal Medicine, Barum Hospital, Vestre Viken Hospital Trust, N-1346 Gjøttum, Norway. 4Department of Medical Research, Barum Hospital, Vestre Viken Hospital Trust, N-1346 Gjøttum, Norway. 5Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, NTNU, Trondheim, Norway. 6Department of Cardiology, St. Olavs Hospital, Trondheim University Hospital, Norway. 7Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, NTNU, Trondheim, Norway. 8Department of Cardiology, University Hospital of North Norway, Tromso, Norway. 9Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway. 10Department of Internal Medicine, Barum Hospital, Vestre Viken Hospital Trust, N-1346 Gjøttum, Norway. 11School of Public Health and Community Medicine, Institute of Medicine, University of Gothenburg Sahlgrenska Academy, Goteborg, Sweden. 12Department of Internal Medicine, Barum Hospital, Vestre Viken Hospital Trust, N-1346 Gjøttum, Norway.
Hospital, Trondheim, Norway. 2Department of Community Medicine, Faculty of Health Sciences, UIT The Arctic University of Norway, Tromsø, Norway. 3Faculty of Medicine, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.

Contributors KRJ drafted the manuscript and performed all statistical analyses. KRR, AHR, BM and MM came up with the idea and design of the study. M-LL, AHR, ES and MM contributed to acquisition and interpretation of the data. TW provided expert advice and supervision of the statistical analyses. All authors contributed to conception of the work and made critical revision of the manuscript for key intellectual content. KRJ is responsible for the overall content as the guarantor.

Funding KRJ was funded by the Northern Norway Regional Health Authority (grant number HNF1568-21). The Birkebeiner Ageing Study has been funded by the Kavli Research Centre for Ageing and Dementia and the Norwegian Extra Foundation.

Competing interests M-LL has received lecture fees from Bayer, Sanofi and BMS/Pfizer not related to this study. MM has received lecture fees from Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, mSD and Pfizer not related to this work.

Patient consent for publication Not applicable.

Ethics approval This study was approved by the Norwegian Data Inspectorate and Health Research Ethics (REK: 2020-17586) and complies with Declaration of Helsinki. All participants gave an informed and written consent to participate.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. The data underlying this article are not publicly available. The data underlying this article cannot be shared publicly due to GDR regulations but is available on request. The legal restrictions on data availability are set by the Tromso Study Data and Publication Committee in order to control for data sharing, including publication of datasets with the potential of reverse identification of de-identified sensitive participant information. The data can however be made available on application to the Tromso Study Data and Publication Committee. Contact information: The Tromso Study, Department of Community Medicine, Faculty of Health Sciences, UIT The Arctic University of Norway; e-mail: tromsouf@uit.no. The datasets generated in BIOS are not publicly available as the study is not yet completed but may be available on reasonable request. The Stata code used for the main analysis is available on reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commericially and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Kristoffer Robin Johansen http://orcid.org/0000-0002-0137-1404
Kim Arne Heitmann http://orcid.org/0000-0002-3963-7645
Maja-Lisa Lachen http://orcid.org/0000-0002-8532-6573
Bente Morseth http://orcid.org/0000-0002-7973-0342

REFERENCES


